Molecular marker for cancer stem cell
View Patent ↗A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.
1. An isolated peptide which is 10 to 11 amino acids long, and is
(i) Or7c1 93: TYAGCLSQIF (SEQ ID NO: 75), or
(ii) Or7c1 93: TYAGCLSQIF (SEQ ID NO: 75) in which the second amino acid from N-terminal is substituted to tryptophan, phenylalanine or methionine and/or the C-terminal amino acid is substituted to leucine, isoleucine, tryptophan or methionine in the polypeptide;
wherein said isolated peptide has HLA-A24 binding ability,
wherein one amino acid is optionally added to an N-terminal end or C-terminal end of the peptide of (i) or (ii).
2. A pharmaceutical composition that comprises at least one of the isolated peptides according to claim 1 as an active ingredient.
3. An isolated peptide according to claim 1 , wherein the isolated peptide is Or7c1 93: TYAGCLSQIF (SEQ ID NO: 75).
4. A pharmaceutical composition that comprises at least one of the isolated peptides according to claim 3 as an active ingredient.
5. A method for inducing CTL comprising a step of contacting a cell population comprising blood mononuclear cells with an isolated peptide according to claim 1 .
6. A method for inducing CTL comprising a step of contacting a cell population comprising blood mononuclear cells with an isolated peptide according to claim 3 .